Abstract
Diabetes, as is well known, makes the patient heterogeneous. Under the name of diabetes is associated a whole set of diseases characterized mainly by and carried out diagnostic symptoms - hyperglycemia.
Keeping glycemia in a physiological state is the result of complex complex regulation, which must have a primarily large margin and be used to provide fine control options. Hyperglycemia is a symptomatic symptom when a certain limit is reached.
Thus, it cannot be divided that the first attempts to treat diabetes meant an effort to eliminate the symptoms. It has been an enormous influence of medical science to determine how glycemic control actually works in a healthy organism and then to verify the overall logical assumption that the goal of diabetes treatment should not only be in accordance with the asymptomatic condition, but in normoglycemia.
Thus, the developmental therapies of diabetes have reached a point where procedures that are better or worse (but so far always uncomplicated) imitate the physiological regulation of glycemia have been and are being developed, with the aim of commonly reaching normoglycemic values in diabetics. It should be emphasized that udiabetics is present with other deviations of metabolism and the internal environment, which negatively affect its life prognosis.
At the same time as optimal strategies for the treatment of hyperglycemia, therapeutic procedures are therefore being developed that would be positively influenced by pathological findings. It is also necessary to distinguish that the treatment of diabetics can always be functional, always an example of research organization and quality.
The system of diabetological outpatient clinics / counseling centers was very progressive at the time of its establishment. As the only country, the intensified insulin regimen became the standard treatment for type 1 diabetics.
Now we are at a time when we are going to introduce as a certain standard vinzulin treatment of treatment with human insulin, ie insulin that has the same molecule with sinzulin produced by the human body. Nevertheless, this standard does not seek optimal approaches to physiological insulin secretion.
This was the main impetus for the development of new "insulin analogues", which would allow even closer to the physiological regulation of glycemia, respectively. insulin secretion. I would like to remind you that this is how medicine enters a qualitatively new phase of development.
Create and use something that is an "enhanced imitation". It should be remembered that the only reason why this is the case is that we have not yet been able to suffice in another way, in another physiological way.
I am thinking in particular of the energy development of a full-fledged beta-cell replacement of the pancreas. Not only patients but also doctors are waiting for this method of treatment.
Once brought to a certain perfection and economic feasibility, this will also mean minimizing fuel consumption to tie the reason to look for optimal analogs, as well as alternative routes of administration.
